Clinical Trials

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Anus Neoplasms, Appendiceal Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lip Neoplasms, Lung Neoplasms, Mesothelioma, Mouth Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Ductal, Small Cell Lung Carcinoma

NCT06105008 2024-08-23

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

NCT05039931 2024-07-18

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

BreastThoracic

Breast Neoplasms, Lung Neoplasms

NCT05212701 2024-04-30

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Phase EARLY_PHASE1 Withdrawn

Breast Neoplasms, Fatigue

NCT05465590 2023-12-21

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

NCT05600582 2023-10-18

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

NCT05191004 2023-07-11

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Breast Neoplasms

NCT04675450 2023-06-08

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Breast Neoplasms, Peripheral Nervous System Diseases

NCT05079360 2023-03-24

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Breast Neoplasms

NCT04252768 2023-03-22

AIPAC-002

Breast Neoplasms

NCT01792882 2023-02-28

GBCPRT0008

BreastGastrointestinalGenitourinaryOther hematologic neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05041972 2022-09-13

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

BreastGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02201381 2022-07-18

METRICS

BreastCNSGastrointestinalGynecologic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02569489 2022-07-18

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Breast Neoplasms

NCT02562612 2022-07-01

Study of SM-88 in Advanced Cancers

Breast Neoplasms

NCT05234606 2022-04-12

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

BreastGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Triple Negative Breast Neoplasms

NCT02850419 2022-04-07

EURO-DIGNITY

Breast Neoplasms

NCT03682744 2022-04-06

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

BreastGastrointestinalGynecologic

Breast Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04655183 2021-06-30

Study of M4344 in Combination With Niraparib

Breast Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03658213 2021-05-10

LARES

Breast Neoplasms

NCT03740945 2020-07-31

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

Breast Neoplasms, Atrophic Vaginitis

NCT04332549 2020-06-01

To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer

Breast Neoplasms

NCT02018419 2020-01-22

MBC

Breast Neoplasms

NCT03988114 2019-09-06

proMONARCH

Phase 4 Withdrawn

Breast Neoplasms

NCT03127332 2019-01-31

Metastatic Breast Cancer Treatment Planning

Phase NA Withdrawn

Breast Neoplasms

NCT03616457 2018-10-26

AMELIA

Breast Neoplasms

NCT02929576 2018-10-22

ENDEAR

Breast Neoplasms, Neoplasm Metastasis

NCT02505698 2018-04-11

A Data Collection Study for the Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment

Breast Neoplasms

NCT03081234 2018-03-15

EarLEE-2

Breast Neoplasms

NCT00615524 2018-01-12

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

NCT02768714 2017-09-15

Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy

Breast Neoplasms

NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Phase 2/3 Withdrawn

Breast Neoplasms

NCT01205217 2017-06-07

ELATE

Breast Neoplasms

NCT01029977 2017-04-27

Imaging Modality Effects on the Multi-dimensional InfraRed Analysis (MIRA) Technology

Breast Neoplasms

NCT02685306 2017-03-09

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02616224 2017-02-23

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

NCT01640847 2017-02-07

MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases

BreastSarcomaThoracic

Adenocarcinoma, Bone Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01959867 2017-01-10

SurgiMend in Two-stage Implant-based Breast Reconstruction in Patients With Pre-Mastectomy Radiotherapy

Phase NA Withdrawn

Breast Neoplasms

NCT00774241 2016-11-02

PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer

Phase 4 Withdrawn

Breast Neoplasms

NCT00964704 2016-11-02

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Breast Neoplasms

NCT01156961 2016-11-02

A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)

Phase 4 Withdrawn